NEW YORK (GenomeWeb News) – Stocks for 'omics tools and molecular diagnostics firms climbed in September amid a general upswing for biotech stocks.

Among the 30 firms that comprise the GenomeWeb Daily News Index, only four saw a decline in their share price over the course of the month, and not a single stock was down in the double digits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.